Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Oh-Biologika-2023-17 - Bevacizumab

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Alitretinoin (Atc Code According to Who: D11ah04)

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Omalizumab (R03dx05) as Part of a So-Called Open House Model.

Drugs Containing the Active Substance Nilotinib (Atc: L01ea03)

Medicines Containing the Active Ingredient Interferon Beta-1B (Atc: L03ab08)

Open House Discount Contracts 2023-08

Medicines Containing the Active Ingredient Budesonide (Atc: A07ea06)

Open House Discount Drug Contracts Epinephrine, Atc C01ca24

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Felbamate, Atc N03ax10 for the Period August 1St, 2023 - July 31St, 2025